ASCO 2025 | The use of olutasidenib in R/R AML: an analysis of outcomes by number of prior treatment regimens

So, olutasidenib is a new generation IDH1 inhibitor, which was approved in the past for treatment of patients with relapsed/refractory IDH1 mutant-disease. This is the second IDH inhibitor that we have for this patient population, the other one being ivosidenib. But there’s been some confusion about which particular settings would this be useful to be used in, and is it efficacious after multiple lines of therapy?

So I presented a poster during this ASCO 2025 meeting that looked at the outcomes of olutasidenib based on prior lines of therapy. And what we found was that this is a highly effective drug for this patient population. Obviously, lesser lines of therapy are associated with better response, but there still is efficacy when used in the second and third line setting. And previously published or demonstrated is case studies where in the upfront and the trials where we looked at relapsed/refractory AML, that this was effective in patients after prior ivosidenib, as well as, interestingly, after prior venetoclax. So we think that this is a newer generation IDH inhibitor that has preserved efficacy, tolerability, and can be used in this setting to continue to prolong patient survival, independent of the lines of therapy that they’ve had previously.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.